LEADER 01386nam 2200349 n 450 001 996395609503316 005 20221107142900.0 035 $a(CKB)3810000000014365 035 $a(EEBO)2240931556 035 $a(UnM)99122376800971 035 $a(EXLCZ)993810000000014365 100 $a19910417d1551 uy 0 101 0 $alat 135 $aurbn||||a|bb| 200 10$aAbsoluta de Christi domini et Catholicae eius ecclesiae sacramentis, tractatio, autore Henrico Bullengero$b[electronic resource] $eCui adiecta est eiusdem argumenti epistola, per Ioannem a? Lasco Baronem Poloniae ante quinquennium scripta. Accessit rerum ac uerborum copiosus index. 210 $aLondini $cExcudebat Stephanus Myerdmannus$dAn. 1551. Men. Apri. [Apr. 1551] 215 $a[1]+ p 300 $aFragment; consists of t.p. only. 300 $aReproduction of original in: British Library. 330 $aeebo-0018 606 $aSacraments$xCatholic Church 615 0$aSacraments$xCatholic Church. 700 $aBullinger$b Heinrich$f1504-1575.$0206154 701 $a?aski$b Jan$f1499-1560.$0225761 801 0$bCu-RivES 801 1$bCu-RivES 801 2$bCStRLIN 801 2$bCu-RivES 906 $aBOOK 912 $a996395609503316 996 $aAbsoluta de Christi domini et Catholicae eius ecclesiae sacramentis, tractatio, autore Henrico Bullengero$92375447 997 $aUNISA LEADER 08897nam 2202653z- 450 001 9910557631703321 005 20231214133152.0 035 $a(CKB)5400000000045097 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/68656 035 $a(EXLCZ)995400000000045097 100 $a20202105d2020 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aPeptides for Health Benefits 2019$eVolume 1 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2020 215 $a1 electronic resource (340 p.) 311 $a3-03936-080-9 311 $a3-03936-081-7 330 $aIn recent years, peptides have received increased interest from the pharmaceutical industry. The high potency, specificity, and safety profile are the main strengths of bioactive peptides as new and promising therapies that may fill the gap between small molecules and protein drugs. These positive attributes have renewed interest in the discovery, optimization, and development of peptides as pharmacological therapy. Among bioactive peptides, those released from food sources have acquired importance as nutraceutical and active components in functional foods because they possess regulatory functions that can lead to health benefits. This Special Issue covers a selection of recent research papers and reviews in the field of bioactive peptides. It covers all aspects of peptide research in relation to health promotion. In particular, it emphasizes current knowledge and research trends concerning bioactive peptides, including identification and quantification of peptides from new sources, methods for their production and purification, structure?function relationships, mechanisms of action, in vitro and in vivo assays for the evaluation of their bioactivity, physiological evidence to support health benefits, and peptide stability and bioavailability. Papers regarding the development of new drugs, functional foods, or nutraceuticals based on bioactive peptides were also considered. 517 $aPeptides for Health Benefits 2019 606 $aResearch & information: general$2bicssc 606 $aBiology, life sciences$2bicssc 610 $aantihypertensive peptides 610 $afunctional food 610 $afood-derived 610 $afermentation 610 $aChlorella sorokiniana 610 $ain silico 610 $aBIOPEP-UWM database 610 $aproteomics 610 $abioactive peptides 610 $anano liquid chromatography tandem mass spectrometry (nanoLC-nanoESI MS/MS) 610 $aapolipoprotein E 610 $aamyloid fibrils 610 $aAlzheimer's disease 610 $a?? oligomer 610 $aamyloid 610 $aA? peptide 610 $aglioma 610 $aplatelets 610 $aantiproliferative assay 610 $aconjugation 610 $adocetaxel 610 $adoxorubicin 610 $aextra domain B 610 $afibronectin 610 $aFmoc/tBu 610 $apeptide-drug conjugate 610 $aprostate cancer 610 $asolid-phase synthesis 610 $atargeting 610 $aacrylamide 610 $aenteric nervous system 610 $agalanin 610 $apig 610 $astomach 610 $aformyl peptide receptors 610 $aligands 610 $adiseases 610 $apolymicrobial biofilms 610 $aintragenic antimicrobial peptide 610 $aHs02 610 $aPseudomonas aeruginosa 610 $aStaphylococcus aureus 610 $aosteostatin 610 $aarthritis 610 $ainflammation 610 $aimmune response 610 $acartilage destruction 610 $abone erosion 610 $acollagen 610 $ahydrolysis 610 $aenzyme 610 $amolecular weight 610 $asheepskin 610 $aNF-?B 610 $adry-cured pork ham 610 $aangiotensin I converting enzyme 610 $aendothelial dysfunction 610 $amolecular blind docking 610 $aLactoferricin B (Lfcin B) 610 $aHistatin-5 610 $aantimicrobial peptides (AMPs) 610 $aantifungal activity 610 $aproteome microarray 610 $asynergy 610 $atemporin 610 $aMRSA 610 $aantimicrobial peptide 610 $ahuman keratinocytes 610 $apseudin-2 610 $aantisepsis, peptide antibiotics 610 $aneurotensin 610 $aasthma 610 $aT cells 610 $aIn situ tetramer staining 610 $aMHC tetramer 610 $aantigen-specific 610 $aconfocal microscopy 610 $afresh tissue 610 $avelvet antler 610 $aalcalase hydrolysate 610 $aantioxidant peptide 610 $aprotection ability 610 $aoxidative stress 610 $aCrassostrea angulata 610 $apidotimod 610 $aCXCR3 610 $amonocyte 610 $amigration 610 $aPI3K/Akt pathway 610 $aT cell 610 $aimmunomodulant 610 $ahost defense peptides 610 $amembrane activity 610 $acopper 610 $apiscidins 610 $aClostridioides difficile 610 $aprolactin-releasing peptide 610 $aGPR10 610 $aRF-amide peptides 610 $afood intake regulation 610 $aenergy expenditure 610 $aneuroprotection 610 $asignaling 610 $agender differences 610 $adyslipidemia 610 $aobesity 610 $ahyperglycemia 610 $apulmonary emphysema 610 $aendothelial progenitor cells 610 $aangiogenic precursor cells 610 $apegylated glucagon-like peptide 1 610 $aand endothelial regeneration 610 $amiiuy croaker (Miichthys miiuy) 610 $aswim bladder 610 $aFPYLRH 610 $aantioxidant activity 610 $acytoprotective effect 610 $aantimicrobial peptides 610 $aantimicrobial resistance 610 $aAMP identification and design 610 $abiosynthesis 610 $amode of action 610 $aphysico-chemical properties 610 $atherapeutic potential 610 $ainsects 610 $aCecropins 610 $aCec-analogs 610 $aMDR infectious diseases 610 $aairway inflammation 610 $anon-atopic asthma 610 $ahybrid peptide 610 $apro-inflammatory cytokines 610 $asPLA2 610 $aMDA 610 $adatabase 610 $aproteolysis 610 $aSMILES code 610 $afoods 610 $anutrition 610 $achronic diseases 610 $anutraceuticals 610 $apeptide vaccine 610 $aimmune checkpoint inhibitor 610 $ahumanized mouse 610 $acancer antigen 610 $aimmune suppression 610 $avasoactive intestinal peptide 610 $aVPAC1 receptor 610 $aVPAC2 receptor 610 $arheumatic diseases 610 $ainflammatory bowel disease 610 $acentral nervous system diseases 610 $atype 1 diabetes 610 $aSjo?gren's syndrome 610 $abiomarkers 610 $ahuman antimicrobial peptides 610 $adefensins 610 $acathelicidins 610 $aanti-inflammatory 610 $apro-inflammatory 610 $apeptide 610 $acombinatorial library 610 $alibrary design 610 $ascreening 610 $amutagenesis 610 $aprolyl-hydroxyproline (Pro-Hyp) 610 $ahydroxyprolyl-glycine (Hyp-Gly) 610 $acollagen peptide 610 $afibroblasts 610 $afetal bovine serum (FBS) 610 $aAMD 610 $aCNV 610 $aVEGFR1 610 $amultimeric peptides 610 $aoral delivery 610 $acolorectal cancer 610 $acancer stem cells 610 $achemoprevention 610 $abioactive peptide 610 $alunasin 610 $aACE-inhibitory activity 610 $awhey peptides 610 $amolecular docking 610 $ahypertension 610 $aantibiotic resistance 610 $acystic fibrosis 610 $acryptides 610 $aanti-biofilm peptides 610 $asynergistic effects 615 7$aResearch & information: general 615 7$aBiology, life sciences 700 $aHerna?ndez-Ledesma$b Blanca$4edt$00 702 $aMarti?nez-Villaluenga$b Cristina$4edt 702 $aHerna?ndez-Ledesma$b Blanca$4oth 702 $aMarti?nez-Villaluenga$b Cristina$4oth 906 $aBOOK 912 $a9910557631703321 996 $aPeptides for Health Benefits 2019$93013216 997 $aUNINA LEADER 01185nam 2200409 450 001 9910828077603321 005 20230126214805.0 010 $a3-95934-384-1 035 $a(CKB)3710000000943326 035 $a(MiAaPQ)EBC4741595 035 $a(Au-PeEL)EBL4741595 035 $a(CaPaEBR)ebr11299553 035 $a(OCoLC)964403438 035 $a(EXLCZ)993710000000943326 100 $a20161209h20162016 uy 0 101 0 $ager 135 $aurcnu|||||||| 181 $2rdacontent 182 $2rdamedia 183 $2rdacarrier 200 10$aControlling in Russland $eEntwicklung, kulturelle Einflu?sse und aktueller Stand /$fAndrej Koval 210 1$aHamburg, [Germany] :$cDiplomica Verlag,$d2016. 210 4$dİ2016 215 $a1 online resource (79 pages) 311 $a3-95934-884-3 320 $aIncludes bibliographical references. 606 $aSocial control$zRussia (Federation) 615 0$aSocial control 676 $a303.33 700 $aKoval$b Andrej$01686707 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910828077603321 996 $aControlling in Russland$94059679 997 $aUNINA